| Literature DB >> 16213868 |
Lukas A Hefler1, Christoph Grimm, Michael van Trotsenburg, Friedrich Nagele.
Abstract
In the present nonrandomized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole (0.25 mg anastrozole/d for 6 months) in the treatment of women with histologically proven rectovaginal endometriosis. In a series of 10 patients, dysmenorrhea, physical and social functioning, but not chronic pelvic pain and dyspareunia, improved during therapy.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16213868 DOI： 10.1016/j.fertnstert.2005.04.059
Source DB: PubMed Journal: Fertil Steril ISSN： 0015-0282 Impact factor: 7.329